Patent · US Expired

Use of ibandronate for promoting osseointegration of endoprostheses

US6680307B1 · kind B1 · utility

7Cited by

3References

3Claims

0Family size

Assignee

Roche Diagnostics GMBH · DE

Inventors

Frieder Bauss · Lambsheim, DE
Andreas Kurth · Braunschweig, DE

Key dates

Filing date	May 31, 2001
Grant date	Jan 20, 2004
Priority date	—
Expiry date	May 31, 2021

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P19/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to use of ibandronic acid (1-hydroxy-3-(N-methyl-N-pentyl)aminopropyl-1,1-diphosphonic acid) or physiologically compatible salts or esters thereof for improving the osseointegration of cement-free anchored endoprostheses. Ibandronate or salts thereof is applied for a short time immediately after insertion of an endoprosthesis, with the surprising result that secondary stability of the implant is obtained in only 5 weeks or less after the operation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.